Analyst Price Targets — DVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 11:49 am | — | Truist Financial | $250.00 | $235.58 | TheFly | DaVita price target raised to $250 from $205 at Truist |
| July 10, 2026 10:17 am | — | UBS | $270.00 | $229.48 | TheFly | DaVita price target raised to $270 from $235 at UBS |
| July 8, 2026 10:20 am | — | Barclays | $218.00 | $234.31 | TheFly | DaVita price target raised to $218 from $194 at Barclays |
| May 8, 2026 11:56 am | — | Truist Financial | $205.00 | $194.39 | TheFly | DaVita price target raised to $205 from $158 at Truist |
| May 7, 2026 9:46 am | Andrew Mok | Barclays | $194.00 | $193.88 | TheFly | DaVita price target raised to $194 from $158 at Barclays |
| May 6, 2026 8:37 am | Pito Chickering | Deutsche Bank | $220.00 | $157.04 | TheFly | DaVita upgraded to Buy from Hold at Deutsche Bank |
| February 5, 2026 3:04 pm | — | Truist Financial | $158.00 | $144.42 | TheFly | DaVita price target raised to $158 from $128 at Truist |
| February 4, 2026 11:34 am | — | UBS | $190.00 | $134.73 | TheFly | DaVita price target raised to $190 from $186 at UBS |
| February 3, 2026 10:24 am | — | Barclays | $158.00 | $111.19 | TheFly | DaVita price target raised to $158 from $143 at Barclays |
| October 30, 2025 10:20 am | — | Barclays | $143.00 | $126.56 | TheFly | DaVita price target lowered to $143 from $149 at Barclays |
Latest News for DVA
DaVita HealthCare (DVA) reached $236.97 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.
DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $232.8, denoting a +1.45% move from the preceding trading day.
Greg Abel may have taken over as CEO, but he's not the only one making key investment decisions at Berkshire Hathaway. Berkshire's positions in DaVita and SiriusXM, reportedly selected by Ted Weschler, who manages a portion of the portfolio, have outperformed so far in 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.